DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA

急性粒细胞白血病反应的决定因素

• 批准号: 3556968
• 负责人: HARVEY D PREISLER
• 金额: $ 111.75万
• 依托单位: ROSWELL PARK CANCER INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1980
• 资助国家: 美国
• 起止时间: 1980-09-01 至 1990-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3556968
• 关键词: anthracyclines; antileukemic agent; antineoplastic antibiotics; biopsy; bone marrow; cell population study; cellular oncology; clone cells; combination chemotherapy; cytosine arabinoside; daunorubicin; doxorubicin; drug adverse effect; drug resistance; drug screening /evaluation; flow cytometry; high performance liquid chromatography; human subject; human therapy evaluation; myelogenous leukemia; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer remission /regression; pharmacokinetics; radioimmunoassay; radiotracer

The purpose of the proposed studies is to develop the ability to design individualized treatment regimens for patients with acute myelocytic leukemia (AML). To this end data regarding the clinical characteristics of AML patients is being collected so that the ability of patients to survive intensive remission induction therapy can be estimated. Previously untreated patients are being treated with the standard cooperative group protocols while relapsed patients are being uniformly treated on common protocols. Pretherapy in vitro leukemic cell drug sensitivity studies and all cycle studies will be carried out to assess the usefulness of assays which would be potentially useful for predicting response. Similarly serial bone marrow examinations during therapy and measurements of plasma drug levels achieved during therapy will be carried out to facilitate development of the means to make an early assessment of response to therapy while therapy is being administered.

本课程的目的是培养学生的设计能力